史丹利(002588.SZ):精製磷酸和磷酸鐵裝置預計在10月底至11月左右投產
格隆匯10月22日丨史丹利(002588.SZ)於近期召開業績交流電話會,就“湖北松滋新材料公司新項目的開工和達產情況如何?”,公司表示,松滋新材料公司選礦、硫酸、磷酸、磷銨等主要生產裝置於今年年中投產,目前生產負荷在50%上下,精製磷酸和磷酸鐵裝置預計在10月底至11月左右投產。選礦裝置、硫磺制酸裝置、磷酸裝置都是約50%的生產負荷,磷酸未開滿且濃縮酸未開,蒸汽用於餘熱發電之後仍有部分剩餘,另外前期管道吹掃排空需一定的成本支出。因此,全廠需滿負荷才能較好地降低運營成本,所以松滋新材料公司7至9月虧損約2300萬元,初步預計年底左右能夠達到盈虧平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.